ANGPT2 and colorectal carcinoma: In the present study, we evaluated the efficacy of co-targeting VEGFA and Ang-2 using a bispecific antibody (CrossMab) in combination with chemotherapy compared with standard anti-VEGF/chemotherapy combination regimen in a chemoresistant colorectal carcinoma xenograft model thereby addressing two major problems in therapy of colorectal cancer: chemotherapy resistance and limited response to bevacizumab.